DMT SUIK
Glucocorticoids
Prices & Coupons
Pharmacy | |||
---|---|---|---|
133RD STREET PHARMACY INC
1473 Amsterdam Ave |
$193.24 |
Get Your Coupon | |
AHF PHARMACY
475 Atlantic Ave |
$193.24 |
Get Your Coupon | 1 more results found for AIDS HEALTHCARE FOUNDATION |
AHF PHARMACY
2307 Astoria Blvd |
$193.24 |
Get Your Coupon | |
ALICE RX CORP
231 S 3 Rd St |
$193.24 |
Get Your Coupon | 24 more results found for PHARMACY FIRST |
DANNY'S PHARMACY II
110 W End Ave |
$193.24 |
Get Your Coupon | |
NORTH HUDSON COMMUNITY PHARMACY
5301 Broadway |
$193.24 |
Get Your Coupon | |
PILL CLOUD RX
6010 Queens Blvd |
$193.24 |
Get Your Coupon | |
123 PHARMACY
420 Grand Street |
$194.24 |
Get Your Coupon | 227 more results found for LEADER DRUG STORES INC |
ACME PHARMACY #1083
125 18 Th St |
$195.25 |
Get Your Coupon | 1 more results found for NEW ALBERTSONS LP |
QUICK RX
909 Columbus Ave |
$195.57 |
Get Your Coupon | 1 more results found for MHA LONG TERM CARE NETWORK |
137 MOTT PHARMACY, INC.
137 Mott St |
$196.07 |
Get Your Coupon | 42 more results found for HEALTH MART ATLAS 605 |
79TH STREET PHARMACY
215 W 79 Th St |
$196.07 |
Get Your Coupon | 51 more results found for HEALTH MART ATLAS 630 |
ECHO CARE SPECIALTY PHARMACY
260 Broadway |
$196.07 |
Get Your Coupon | |
A.M. PHARMACY II, INC
223 Grand Street |
$196.16 |
Get Your Coupon | 28 more results found for ALIGNRX (783) |
HUDSON PHARMACY
65 08 Roosevelt Avenue |
$196.16 |
Get Your Coupon | |
A PLUS PHARMACY
634 Summit Ave |
$196.57 |
Get Your Coupon | 31 more results found for EPIC PHARMACY NETWORK INC |
1699 FANCY PHARMACY INC
132 Allen St |
$197.74 |
Get Your Coupon | 77 more results found for ELEVATE PROVIDER NETWORK 904 |
LUZATO MEDICAL GROUP PC
50 E 42 Nd St Rm 508 |
$197.74 |
Get Your Coupon | 8 more results found for ELEVATE PROVIDER NETWORK 959 |
CARE PLUS CVS/PHARMACY #02546
1200 Harbor Blvd |
$198.74 |
Get Your Coupon | 76 more results found for CVS PHARMACY INC |
CVS PHARMACY # 17820
10 Union Sq E |
$198.74 |
Get Your Coupon | 9 more results found for CVS PHARMACY IN TARGET |
CVS PHARMACY #02919
126 Eighth Ave |
$198.74 |
Get Your Coupon | |
WALMART PHARMACY 10-3520
400 Park Place |
$199.57 |
Get Your Coupon | 1 more results found for WALMART STORES INC |
APICHA HEALTH CENTER PHARMACY
400 Broadway |
$201.07 |
Get Your Coupon | 4 more results found for MAXORXPRESS |
CHELSEA ROYAL CARE PHARMACY, INC.
154 9 Th Ave |
$201.07 |
Get Your Coupon | |
CHRONOS PHARMACY
30 96 36 Th Street |
$201.07 |
Get Your Coupon | |
COLUMBIA DRUGS
55 Columbia St |
$201.07 |
Get Your Coupon | |
CONTIGO PHARMACY
3510 Bergenline Ave |
$201.07 |
Get Your Coupon | 23 more results found for GERIMED LTC NETWORK INC |
COSTCO PHARMACY #1062
517 E 117 Th St |
$201.07 |
Get Your Coupon | 1 more results found for COSTCO PHARMACIES |
RITE AID PHARMACY 01225
534 Hudson Street |
$201.07 |
Get Your Coupon | 8 more results found for RITE AID CORPORATION |
ROR MADISON PHARMACY INC
1636 Madison Ave |
$201.07 |
Get Your Coupon | |
RX CENTER
2325 1 St Ave |
$201.07 |
Get Your Coupon | |
ST JOHNS PHARMACY
2980 John F Kennedy Blvd |
$201.07 |
Get Your Coupon | |
TURTLE BAY CHEMISTS
901 2 Nd Ave |
$201.07 |
Get Your Coupon | |
UMR PHARMACY & SURGICAL INC
437 Central Ave |
$201.07 |
Get Your Coupon | |
COMMUNITY, A WALGREENS PHARMACY #16463
29 W 116 Th St |
$207.08 |
Get Your Coupon | 104 more results found for WALGREENS DRUG STORE |
OPTUM PHARMACY 706 INC
3030 47 Th Avenue |
$207.08 |
Get Your Coupon | |
Dosage and administration
DOSAGE AND ADMINISTRATION Dexamethasone sodium phosphate injection, 10 mg/mL– For intravenous and intramuscular injection only. Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and administered by intravenous drip. Solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant. When it is mixed with an infusion solution, sterile precautions should be observed. Since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours. DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT. Intravenous and Intramuscular Injection The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient’s response is satisfactory. If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy. After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response. Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily. If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually. When the intravenous route of administration is used, dosage usually should be the same as the oral dosage. In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. The slower rate of absorption by intramuscular administration should be recognized. Shock There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock. The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: Author Dosage Cavanagh1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg Dietzman2 2 to 6 mg/kg of body weight as a single intravenous injection Frank3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists Oaks4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists Schumer5 1 mg/kg of body weight as a single intravenous injection Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours. Although adverse reactions associated with high dose, short-term corticosteroid therapy are uncommon, peptic ulceration may occur. Cerebral Edema Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective. Acute Allergic Disorders In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, first day , 4 or 8 mg intramuscularly. Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day , 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit. This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit., Intravenous and Intramuscular Injection The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient’s response is satisfactory. If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy. After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response. Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily. If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually. When the intravenous route of administration is used, dosage usually should be the same as the oral dosage. In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. The slower rate of absorption by intramuscular administration should be recognized., Shock There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock. The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: Author Dosage Cavanagh1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg Dietzman2 2 to 6 mg/kg of body weight as a single intravenous injection Frank3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists Oaks4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists Schumer5 1 mg/kg of body weight as a single intravenous injection Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours. Although adverse reactions associated with high dose, short-term corticosteroid therapy are uncommon, peptic ulceration may occur., Cerebral Edema Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective., and Acute Allergic Disorders In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, first day , 4 or 8 mg intramuscularly. Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day , 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit. This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
Indications And Usage
INDICATIONS AND USAGE By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.